Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

As part of its extensive offerings for the eczema community throughout October, NEA hosts The Ecz-hibition, a social ...

USA Today reports on how the former president benefitted after a diagnosis that just years prior would have been terminal. Cancer therapies have enabled him to celebrate his 100th birthday this week.

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...